Daymark Wealth Partners’s Summit Therapeutics SMMT Stock Holding History

Daymark Wealth Partners’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$178K	Buy	+10,500	New	+$157K	﹤0.01%	848

Other funds holding SMMT

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return

Hohimer Wealth Management Seattle, Washington $1.03B AUM 25.45% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Daymark Wealth Partners's SMMT Position: Q3 2026 in Review

Daymark Wealth Partners opened a new position in Summit Therapeutics (SMMT) in Q3 2026: 10,500 shares worth $178K. The stake represents ﹤0.01% of the portfolio and ranks #848 among its holdings.

141 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

Daymark Wealth Partners held 10,500 shares of Summit Therapeutics worth $178K as of Q3 2026.
Summit Therapeutics was a new Daymark Wealth Partners position in Q3 2026.
Summit Therapeutics made up ﹤0.01% of Daymark Wealth Partners's portfolio in Q3 2026, its #848 holding.
141 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Daymark Wealth Partners's 13F filing for Q3 2026, filed 4 Nov 2026.